CHIR99021 is the most selective inhibitor of glycogen synthase kinase 3β (GSK3β, IC50 7nM) reported so far and it does not inhibit cyclin-dependent kinases (CDKs).
CHIR99021 has been shown in long term expansion of murine embryonic stem cells in conjunction with MEK/MAPK inhibitor PD184352 and fibroblast growth factor receptor (FGFR) inhibitor SU5402.
Technical information:
| Chemical Formula: | C22H18CI2N8 | |
| CAS #: | 252917-06-9 | |
| Molecular Weight: | 465.34 | |
| Purity: | >98% | |
| Appearance: | Pale solid | |
| Chemical Name: | 6-((2-((4-(2,4-Dichlorophenyl)-5-(4-methyl-1H-imidazol-2-yl)pyrimidin-2-yl) amino)ethyl)amino)nicotinonitrile |
|
| Solubility: | Up to 25 mM in DMSO |
Shipping Condition: The product is shipped in a glass vial at ambient temperature.
Storage: For longer shelf life, store solid powder at 4oC desiccated, or store DMSO solution at -20oC.
Reference:
| 1. | Ring D et al. (2003). Selective Glycogen Synthase Kinase 3 Inhibitors Potentiate Insulin Activation of Glucose Transport and Utilization In Vitro and In Vivo. Diabetes. 52: 3, 588-595. |
| 2. | Finley D et al. (2004). Glycogen Synthase Kinase-3 regulates IGFBP-1 gene transcription through the Thymine-rich Insulin Response Element. BMC Mol. Biol. 5:15. |
| 3. | Ying Q. et al. (2008) The ground state of embryonic stem cell self renewal. Nature. 453: 519-523. |
Other Information:
Product Specification (pdf)
MSDS (pdf)
